文献速递眼底病与葡萄膜炎

多因素干预对2型糖尿病患者视网膜病变的影响:J-DOIT3随机临床试验的二次分析

Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes: A Secondary Analysis of the J-DOIT3 Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

J-DOIT3多中心开放标签平行组随机临床试验的二次分析,纳入2540例(5080眼)45至69岁合并高血压和/或血脂异常的2型糖尿病患者,随机接受强化治疗或常规治疗,中位随访8.5年。强化治疗与视网膜病变发病风险降低相关(HR 0.83),但与视网膜病变进展无关(HR 1.02)。随机化后1年HbA1c及非严重低血糖均与视网膜病变发病风险升高相关。

要点

  • 强化多因素治疗与视网膜病变发病风险降低相关(HR 0.83;95%CI 0.70-0.98;P=0.03)。
  • 强化治疗与视网膜病变进展无显著关联(HR 1.02;95%CI 0.70-1.49;P=0.93)。
  • 随机化后1年HbA1c与视网膜病变发病相关(HR 1.31),非严重低血糖亦与发病风险升高相关。

核心结论

  • 在随机临床试验背景下,较高的HbA1c和非严重低血糖与2型糖尿病患者视网膜病变发病风险升高相关,即使已实现良好血糖管理且严重低血糖发生率极低。
  • 结果提示严格血糖管理且不发生低血糖的重要性。

研究设计与样本

  • J-DOIT3为多中心、开放标签、平行组随机临床试验,在日本81个中心于2006年6月至2009年3月开展,数据分析于2018年9月至2025年8月进行。
  • 纳入45至69岁合并高血压和/或血脂异常的2型糖尿病患者,随机分配至强化治疗组(血糖、血压、血脂)或常规治疗组,中位随访8.5年。
  • 本报告为视网膜病变事件的二次分析,共2540例参与者(5080眼),平均(SD)年龄59.0(6.3)岁,女性965例(38.0%)。

主要发现

  • 强化治疗与视网膜病变发病风险降低相关(HR 0.83;95%CI 0.70-0.98;P=0.03),但与视网膜病变进展无关(HR 1.02;95%CI 0.70-1.49;P=0.93)。
  • 随机化后1年HbA1c与视网膜病变发病相关(HR 1.31;95%CI 1.13-1.51;P<0.001),调整基线危险因素后仍相关,未观察到明确的HbA1c阈值。
  • 与干预期间无低血糖发作者相比,每年低血糖发作0.5次或以下者发病风险更高(HR 1.25;95%CI 1.02-1.53),每年超过1次者更高(HR 1.85;95%CI 1.39-2.47)。

关键数值与推荐

  • 强化治疗组视网膜病变发病风险低于常规治疗组(HR 0.83;95%CI 0.70-0.98;P=0.03)。
  • 强化治疗组与常规治疗组视网膜病变进展风险无显著差异(HR 1.02;95%CI 0.70-1.49;P=0.93)。
  • 随机化后1年HbA1c每升高1个单位,视网膜病变发病风险HR 1.31(95%CI 1.13-1.51;P<0.001)。
  • 每年低血糖发作0.5次或以下者视网膜病变发病风险HR 1.25(95%CI 1.02-1.53),每年超过1次者HR 1.85(95%CI 1.39-2.47),均以无低血糖发作者为参照。

临床怎么用

  • 原文结论提示严格血糖管理且不发生低血糖的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prevention of diabetic retinopathy is important to keep vision and quality of life. OBJECTIVE: To examine the effects of an intensive multifactorial intervention and hypoglycemia on retinopathy in people with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: J-DOIT3 (Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases) is a multicenter, open-label, parallel-group randomized clinical trial that examined the efficacy of an intensified multifactorial intervention on cardiovascular outcomes and mortality in people with type 2 diabetes aged 45 to 69 years with hypertension and/or dyslipidemia. The study was conducted at 81 sites in Japan from June 2006 to March 2009, and data analysis was performed from September 2018 to August 2025. INTERVENTIONS: Participants were randomly assigned to intensive therapy for glucose, blood pressure, and lipids or conventional therapy and were followed up for a median duration of 8.5 years. MAIN OUTCOMES AND MEASURES: This study is a secondary analysis of retinopathy events of the secondary outcomes, composed of onset of retinopathy, progression of retinopathy, and loss of vision likely due to retinopathy. RESULTS: Among 2540 total participants (5080 eyes) randomly assigned to intensive therapy or conventional therapy, mean (SD) age was 59.0 (6.3) years, and 965 participants (38.0%) were female. Intensive therapy was associated with a risk reduction in onset of retinopathy (hazard ratio [HR], 0.83; 95% CI, 0.70-0.98; P = .03) but not with progression of retinopathy (HR, 1.02; 95% CI, 0.70-1.49; P = .93). Hemoglobin A1c (HbA1c) at 1 year after randomization was associated with onset (HR, 1.31; 95% CI, 1.13-1.51; P < .001), even after adjustment for baseline risk factors (ie, lower body mass index, longer duration of diabetes, higher fasting plasma glucose, higher blood pressure, and comorbid nephropathy), with no clear HbA1c threshold observed. Moreover, compared with those without a hypoglycemic episode during the intervention, the risk of onset was higher in those with 0.5 hypoglycemic episodes per year or fewer (HR, 1.25; 95% CI, 1.02-1.53) and even higher in those with more than 1 hypoglycemic episode per year (HR, 1.85; 95% CI, 1.39-2.47). CONCLUSIONS AND RELEVANCE: This secondary analysis of the J-DOIT3 randomized clinical trial shows that in a randomized clinical trial setting, higher HbA1c and nonsevere hypoglycemia are associated with higher risk of onset of retinopathy in people with type 2 diabetes, even when good glycemic management, with a very low incidence of severe hypoglycemia, is achieved, suggesting the importance of strict glycemic management without any hypoglycemia. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00300976.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sasako T, Ueki K, Miyoshi K, et al. Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes: A Secondary Analysis of the J-DOIT3 Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 41129145. doi:10.1001/jamaophthalmol.2025.3819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。